Health and wellness company Perrigo Company plc (NYSE:PRGO)(TASE:PRGO) reported on Wednesday the receipt of the final approval from the US Food and Drug Administration (FDA) for its AB rated Abbreviated New Drug Application referencing Zovirax Cream, 5% (acyclovir cream, 5%) against herpes viruses.
The company added the generic Zovirax Cream, 5% (acyclovir cream, 5%) was developed in collaboration with Sol-Gel Technologies Ltd (NASDAQ:SLGL).
Following the US FDA's approval, the company anticipates launching Zovirax Cream, 5% (acyclovir cream, 5%) this month.
For the 12 months ending December 2018, the annual market sales were approximately USD92m as measured by IQVIA, concluded the company
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical